Lenabasum Showing Promise in Systemic Scleroderma

The oral, synthetic, nonimmunosuppressive small molecule improves outcome scores for patients with few treatment options, new research shows.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply